- Learn how AI-driven approaches integrate multiomics data, including genomics, proteomics, and transcriptomics, to identify potential drug targets and disease biomarkers for complex diseases.
- Explore how AI models synthesize cross-omic data and real-time multiomic information to uncover novel biological mechanisms, identify potential biomarkers and enable precision medicine.
Raju Pusapati
Dr. Raju Pusapati is a biologist and drug discovery scientist with a distinguished 15+ year career spanning top-tier institutions like Genentech, Exelixis, and emerging biotech ventures. Trained at Harvard and Genentech, his expertise lies in translating basic cancer biology—including the discovery of novel signaling pathways and resistance mechanisms—into viable clinical candidates.
As a project leader and biology lead, he has a proven track record of steering oncology programs from target validation and lead identification through to Go/No-Go decisions, with publications in top-tier journals such as Cancer Cell and Nature Chemical Biology. His hands-on experience encompasses the full spectrum of pre-clinical work, including biomarker strategy, PK/PD, and managing complex internal and external collaborations.
In his current role as Vice President of Life Sciences at Solix Technologies, Dr. Pusapati leverages this deep industry background to bridge the gap between biology and technology. He leads the charge in adopting Solix's CDP and Enterprise AI platforms, empowering life sciences companies to unlock data-driven insights and accelerate therapeutic innovation. He brings this unique, dual perspective to the panel “AI and Multi-omics Integration for Enhanced Target Identification and Validation".
Kiran Nistala
Harris Bell-Temin
